Table 1.
Baseline characteristics ‘Plants for Joints’ RA trial
| Plants for Joints group | Control group | |
|---|---|---|
| Characteristic | (n = 40) | (n = 37) |
| Age, mean (s.d.), years | 56.4 (13.4) | 52.8 (10.3) |
| Female sex, number (%) | 36 (90) | 35 (95) |
| RF positive, number (%) | 20 (50) | 29 (78) |
| ACPA positive, number (%) | 24 (60) | 26 (70) |
| Seropositive, number (%) | 26 (65) | 31 (84) |
| Disease duration, mean (s.d.), years | 10 (9) | 8 (8) |
| BMI, mean (s.d.), kg/m2 | 27.1 (4.6) | 25.1 (3.7) |
| DAS28, mean (s.d.) | 3.90 (0.7) | 3.78 (0.7) |
| Erosive disease, number (%) | 23 (58) | 15 (43) |
| Medication for RA, number (%) | ||
| MTX monotherapy | 11 (28) | 3 (8) |
| MTX combination therapy | 12 (30) | 7 (19) |
| Other csDMARD monotherapy | 3 (8) | 1 (3) |
| Other csDMARD combination therapy | 2 (5) | 2 (5) |
| bDMARD | 6 (15) | 7 (19) |
| tsDMARD | 0 (0) | 3 (8) |
| Glucocorticoids | 2 (5) | 1 (3) |
| No medication | 4 (10) | 13 (35) |
| Previous medication for RA | ||
| csDMARD treatment, median (range), count | 1 (0–4) | 0 (0–4) |
| bDMARD treatment, median (range), count | 0 (0–4) | 0 (0–5) |
| tsDMARD treatment, median (range), count | 0 (0–0) | 0 (0–1) |
| Glucocorticoids, number (%) | 9 (23) | 9 (24) |
| Only csDMARD treatment, number (%) | 10 (25) | 8 (22) |
| 1 bDMARD treatment, number (%) | 6 (15) | 2 (5) |
| 2 or more bDMARD treatments, number (%) | 4 (10) | 4 (11) |
| No prior treatment, number (%) | 5 (13) | 13 (35) |
| Medication for diabetes, number (%) | 2 (5) | 1 (3) |
| Medication for hypertension, number (%) | 6 (15) | 3 (8) |
| Medication for hyperlipidaemia, number (%) | 4 (10) | 3 (8) |
Previous medication for DMARD treatment refers to the median (range) number of DMARDs used before baseline medication and the number (%) of participants who had a certain treatment before baseline. Seropositive: positive for RF or ACPA; BMI: body weight in kilograms divided by the square of the height in metres; DAS28: 28-joint DAS; csDMARD: conventional synthetic DMARD; bDMARD: biological DMARD; tsDMARD: targeted synthetic DMARD.